Immatics Presents Phase I Data from ACTolog® Multi-Target Pilot Study IMA101 at the 35th Annual SITC Conference
November 10 2020 - 7:00AM
- Multi-target Adoptive Cell Therapy
(ACT) with endogenous T cells against defined pHLA targets
demonstrates feasibility, tolerability and high T-cell
persistence.
- Clinical courses observed in patients
indicate COL6A3 exon 6 as a potentially valuable tumor target for
continued evaluation.
- The data support further exploration
of a multi-target ACT approach using potent T cell receptors
(TCRs)
Tuebingen,
Germany and Houston, Texas, November 10,
2020 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a
clinical-stage biopharmaceutical company active in the discovery
and development of T cell redirecting cancer immunotherapies,
announced today that the Company will present Phase I results from
their ACTolog® program IMA101 at the 35th Annual SITC Meeting, held
virtually from November 9-14, 2020. ACTolog® is a pilot study for a
personalized multi-TCR-T approach that aims to address current
challenges for effective cancer immunotherapy, such as tumor
heterogeneity and tumor immune escape. The data to be presented
demonstrate the feasibility of the approach while also showing the
therapy is well tolerated. In addition, case studies within the
treated patient population support further exploration of a
personalized ACT approach using potent high-affinity TCRs.
The data will be presented at the Society for
Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
on November 11.
Clinical Data Highlights
- 14 patients with relapsed/refractory solid tumors received
adoptive cell therapy IMA101 directed against defined pHLA targets
specific to each patient
- ACTolog® demonstrates feasibility of a multi-target
multi-T cell product approach
- The target positivity rate of 90% demonstrated
that such a multi-target approach leads to minimal patient
attrition during screening due to lack of target expression.
- Each product combination in the ACTolog® multi-target approach
was guided by confirmed target expression in patient-derived
biopsies.
- ACTolog® was well-tolerated in heavily pretreated
patients
- Common adverse events included expected cytopenias, mostly
associated with the lymphodepleting regime and in many cases
accompanied by Grade 1-2 cytokine release syndrome.
- ACTolog® shows remarkable T cell persistence and tumor
infiltration
- ACTolog® treatment resulted in high target-specific T cell
levels and persistence with total frequencies up to ~80% of all
peripheral CD8+ T cells in the blood.
- Target-specific T cells were detectable in post-treatment tumor
biopsies.
- Individual TCRs in the endogenous T cell products showed a
broad range of avidities, however the majority being of low
avidity, reflecting the range to be expected in the natural immune
repertoire.
- ACTolog® revealed long-term disease stabilization in
some patients
- All three patients with prolonged disease stabilization showed
high frequency of target-specific T cells (>40% of CD8+ T cells)
in the blood post-infusion.
- Two of these three patients received a COL6A3 exon 6-specific T
cell product indicating COL6A3 as a potentially valuable tumor
target and targeting the tumor stroma as a promising approach.
- ACTolog® results warrant the further evaluation of a
multi-target ACT approach using potent high-avidity TCRs (i.e.
autologous TCR-engineered T cells)
"We are excited to present the final results of
this personalized adoptive cell therapy against multiple novel
defined peptide-HLA cancer targets at SITC 2020,” said Apostolia
Tsimberidou, M.D., Ph.D., Lead Investigator of the study and
Professor, Department of Investigational Cancer Therapeutics, The
University of Texas MD Anderson Cancer Center. “The target
positivity rate of 90% among HLA-A*02:01 positive patients
highlights that this approach can be applied to a variety of cancer
patients. In addition, we were able to show that the treatment
approach was feasible and, overall, well tolerated. Most notably,
three out of 14 patients had prolonged disease stabilization
lasting well over six months. We believe that these results warrant
the further evaluation of a multi-target adoptive cell therapy
approach using potent high-avidity TCRs possibly combined with
other immunotherapeutic interventions to solidify patient responses
over time.”
“To our knowledge the ACTolog® pilot study is
the first trial to demonstrate feasibility of an actively
personalized T cell therapy approach directed against multiple
targets. Moreover, it supports that targeting COL6A3 exon 6
represents a promising approach to tackling the tumor stroma,”
remarked Harpreet Singh, CEO of Immatics. “The low avidity of the
patients’ own TCR repertoire that we have seen in the study
population, however, demonstrates the need for more potent TCRs to
enable greater therapeutic impact for cancer patients. Our
ACTengine® approach, evaluated currently in three ongoing clinical
trials, is specifically addressing this aspect by genetically
engineering T cells with highly potent TCRs. We look forward to
providing the first clinical data on the ACTengine® trials in the
first quarter of 2021.”
The full poster is available on Immatics’
website using this link.
Notes to Editors
About Immatics’ ACTolog®
ProgramThe ACTolog® trial (IMA101-101) is a clinical pilot
trial to demonstrate tolerability and feasibility of a multi-target
ACT approach. The ACTolog® concept is based on selecting and
expanding a patient’s own autologous T cells dependent on the
detection of ACTolog® targets in the patient’s tumor tissue. The
ACTolog® approach was designed as the first known multi-target
precision immunotherapy delivering a proof-of-principle for a
next-generation multi-TCR-T approach using highly potent TCRs as in
Immatics’ lead product class ACTengine® (TCR-T).
More information on the clinical trials can be
found at the following links: www.immatics.com/clinical-programs
and www.clinicaltrials.gov.
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
For regular updates about Immatics, visit
www.immatics.com. You can also follow us on Twitter and
LinkedIn.
Forward-Looking Statements:
Certain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or Immatics’ future financial or
operating performance. For example, statements concerning the
timing of product candidates and Immatics’ focus on partnerships to
advance its strategy are forward-looking statements. In some cases,
you can identify forward-looking statements by terminology such as
“may”, “should”, “expect”, “intend”, “will”, “estimate”,
“anticipate”, “believe”, “predict”, “potential” or “continue”, or
the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which could cause actual results
to differ materially from those expressed or implied by such
forward looking statements. These forward-looking statements are
based upon estimates and assumptions that, while considered
reasonable by Immatics and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to, various factors beyond management's control including general
economic conditions and other risks, uncertainties and factors set
forth in filings with the Securities and Exchange Commission (SEC).
Nothing in this presentation should be regarded as a representation
by any person that the forward-looking statements set forth herein
will be achieved or that any of the contemplated results of such
forward-looking statements will be achieved. You should not place
undue reliance on forward-looking statements, which speak only as
of the date they are made. Immatics undertakes no duty to update
these forward-looking statements.
For more information, please
contact:
For media enquiries |
Investor Relations Contact |
Jacob Verghese or Stephanie May |
John Graziano |
Trophic Communications |
Solebury Trout |
Phone: +49 89 2388 7731 |
Phone: +1 646-378-2942 |
immatics@trophic.eu |
jgraziano@soleburytrout.com |
Immatics N.V. |
Investor Relations Contact |
Anja Heuer |
Jordan Silverstein |
Corporate Communications |
Head of Strategy |
Phone: +49 89 540415-606 |
Phone: +1 281-810-7545 |
media@immatics.com |
InvestorRelations@immatics.com |
- ACTolog SITC data presentation
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024